Inspiremd Inc (NSPR) Stock Price, Quote & News

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 776 6804

Website: www.inspiremd.com

Address:

6303 Waterford District Drive, Suite 215, Miami, United States

OfficialStocktwitsUser Mar. 20 at 7:57 PM

$NSPR RSI: 50.39, MACD: 0.0048 Vol: 0.09, MA20: 1.73, MA50: 1.70 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

FoxyDreams Mar. 20 at 2:09 PM

•@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of traders on this platform. •If you’re not following yet, you’re missing out. It takes 2 seconds and it’s completely free. 💎 $SLMT $OVID $NSPR $CAST ** on watch

0 · Reply

Jonnie5 Mar. 20 at 1:13 AM

$NSPR well that’s just great guys…my position is skin and bones clinging to life.

0 · Reply

Shshshsshs Mar. 19 at 4:17 PM

$NSPR look this up on the MAUDE FDA list of complaints.

2 · Reply

woodstockery Mar. 19 at 3:15 PM

$NSPR gotta love it

0 · Reply

jensen146 Mar. 18 at 10:37 PM

$NSPR All is positive except the price, and hopefully that will catch up. Last quarter they indicated100 units had been sold in the US, and this quarter indicated nearly 500. Nice 400 percent gain. I believe they sell each unit one at a time. When TCAR is approved will hospitals be able to have stock on hand? It would be nice to see some big purchase orders from hospital chains and the Government. That will allow for exponential growth.

0 · Reply

BrexitIsStupid Mar. 18 at 9:17 PM

$NSPR Disappointing day, even after a good earning report and positive conference call.

1 · Reply

arcuy Mar. 18 at 4:44 PM

$NSPR Q4 2025: Revenue +62% YoY. US revenue +74% sequential. FY2026 guidance $13-15M (+65% growth). TCAR FDA submission done — approval expected Q3, doubles addressable market. C-GUARDIANS II data dropping at Charing Cross April. Raymond Cohen (ex-Axonics/$3.7B exit to BSX) on board. Second manufacturing line established in Charlotte NC. 200+ centers in VAC pipeline. CGuard Prime purpose-built compatible with Silk Road BSX neuroprotection system. 80+ centers already doing cases. Price: $1.70. Figure it out.

0 · Reply

Jackedtothetits42 Mar. 18 at 4:20 PM

$NSPR I really hate that I was right 😭

1 · Reply

LoyalShark Mar. 18 at 3:28 PM

$NSPR Today proves a point. Great news today. Outstanding earnings release yet ... nothing. When no one knows you exist ...it seems no one cares. As with the fda clearances and approvals ...none of the announcements meana thing when you dont have a following. NSPR's IR sucks at creating a following. He doesnt return phones calls. Emails. In my opinion he is one of the bigger POS IR guys i have ever encountered. Fitting that Slosman would hire such a turd. So if you are at Schwab you can effectively buy ZERO shares without buying in person through their trading desk. It cut demand - it hurts shareholders. IT hurts the market. If you are afat Fidelity you cant sell but a few shares without talking directly with the trading desk. These things are an issue that slosman needs to address. Typically it would be IR dealing with it.

1 · Reply

InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript

Mar 18, 2026, 7:00 AM EDT - 3 days ago

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026, 9:00 AM EDT - 12 days ago

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

Jan 20, 2026, 9:00 AM EST - 2 months ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 9:00 AM EST - 2 months ago

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

Nov 24, 2025, 7:30 AM EST - 4 months ago

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Nov 19, 2025, 4:42 PM EST - 4 months ago

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

Nov 4, 2025, 1:06 PM EST - 4 months ago

InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 4 months ago

InspireMD Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 7:30 AM EST - 4 months ago

InspireMD Names Peter A. Soukas, M.D.

Oct 21, 2025, 4:05 PM EDT - 5 months ago

InspireMD to Announce Third Quarter 2025 Financial Results

Sep 17, 2025, 8:00 AM EDT - 6 months ago

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Aug 27, 2025, 9:00 AM EDT - 7 months ago

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 12:30 PM EDT - 8 months ago

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 8 months ago

InspireMD Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 8:31 AM EDT - 8 months ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:30 AM EDT - 8 months ago

InspireMD Announces Combined Financings of $58 Million

Jul 22, 2025, 7:00 AM EDT - 8 months ago

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 9 months ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 9 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 10 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 3, 2025, 4:05 PM EDT - 10 months ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

May 9, 2025, 12:07 PM EDT - 11 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:00 AM EDT - 11 months ago

InspireMD Reports First Quarter 2025 Financial Results

Apr 30, 2025, 9:00 AM EDT - 11 months ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 25, 2025, 9:00 AM EDT - 11 months ago

InspireMD to Announce First Quarter 2025 Financial Results

Mar 26, 2025, 9:00 AM EDT - 1 year ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 12, 2025, 1:53 PM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 7:00 AM EDT - 1 year ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 1 year ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 7:00 AM EST - 1 year ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Dec 9, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Nov 25, 2024, 4:05 PM EST - 1 year ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 12, 2024, 10:20 AM EST - 1 year ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Oct 15, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 8:09 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 1 year ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Jul 30, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

May 28, 2024, 8:53 AM EDT - 1 year ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 14, 2024, 10:50 AM EDT - 2 years ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 2 years ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 7:00 AM EDT - 2 years ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

Apr 3, 2024, 8:59 AM EDT - 2 years ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 2 years ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 6, 2024, 11:30 AM EST - 2 years ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:00 AM EST - 2 years ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

OfficialStocktwitsUser Mar. 20 at 7:57 PM

0 · Reply

FoxyDreams Mar. 20 at 2:09 PM

0 · Reply

Jonnie5 Mar. 20 at 1:13 AM

$NSPR well that’s just great guys…my position is skin and bones clinging to life.

0 · Reply

Shshshsshs Mar. 19 at 4:17 PM

$NSPR look this up on the MAUDE FDA list of complaints.

2 · Reply

woodstockery Mar. 19 at 3:15 PM

$NSPR gotta love it

0 · Reply

jensen146 Mar. 18 at 10:37 PM

0 · Reply

BrexitIsStupid Mar. 18 at 9:17 PM

$NSPR Disappointing day, even after a good earning report and positive conference call.

1 · Reply

arcuy Mar. 18 at 4:44 PM

0 · Reply

Jackedtothetits42 Mar. 18 at 4:20 PM

$NSPR I really hate that I was right 😭

1 · Reply

LoyalShark Mar. 18 at 3:28 PM

1 · Reply

arcuy Mar. 18 at 2:31 PM

$NSPR Do you guys think all this work to make CGuard compatible with Silk Road’s TCAR platform is mainly meant to accelerate organic growth, or are they positioning the company as a future takeout target for Boston?

0 · Reply

Threeways Mar. 18 at 2:01 PM

$NSPR well that blows. Straight faded

0 · Reply

Jackedtothetits42 Mar. 18 at 1:34 PM

$NSPR and down she goes

0 · Reply

topstockalerts Mar. 18 at 1:31 PM

$NSPR history of sudden spikes around news. Volume usually shows up before the actual move.

0 · Reply

arcuy Mar. 18 at 1:19 PM

$NSPR Guys, do you know what is the cheapest way to fly to BOS?

0 · Reply

topstockalerts Mar. 18 at 1:06 PM

Pre Market Top Gainers PT2 $KC $FAAR $HIT.X $OVID $NSPR

0 · Reply

HOBOWITHASHOTGUN Mar. 18 at 1:04 PM

$NSPR Ah - nothing beats a positive earnings report..

0 · Reply

cekici1972 Mar. 18 at 1:02 PM

$NSPR are we gonna see some light one day with this stock?

0 · Reply

BioBuddha Mar. 18 at 12:58 PM

$NSPR the discussion is rich and deep. No need to sell. This is on a good trajectory

0 · Reply

deesht Mar. 18 at 12:47 PM

$NSPR positive earnings with strong insider interest

0 · Reply

LoyalShark Mar. 18 at 12:42 PM

$NSPR Nice!

0 · Reply

arcuy Mar. 18 at 12:31 PM

$NSPR call live now

0 · Reply

Market Cap	75.84M
Revenue (ttm)	7.01M
Net Income (ttm)	-32.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-456.63%
Debt to Equity Ratio	0.00

Volume	119,200
Avg Vol	36,172
Day's Range	N/A - N/A
Shares Out	42.37M
Stochastic %K	54%
Beta	0.87
Analysts	Strong Sell
Price Target	$5.00